4SCAR19 and 4SCAR22: Clinical Trials

1 trial of 4SCAR19 and 4SCAR22, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1
Phase 21Terminated 1

Follow 4SCAR19 and 4SCAR22: new trials by email Literature Review of 4SCAR19 and 4SCAR22 trials Research Report on 4SCAR19 and 4SCAR22

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute1002025-08-012026-08-24

Conditions studied

Leukemia, B-Cell (1)

Sponsors

Shenzhen Geno-Immune Medical Institute (1)

Countries

China (1)

Top investigators

Lung-Ji Chang, PhD (1)

Results publications

PMID 30444200